

# **Pd(II) and Pt(II) trinuclear chelates with spermidine: selective anticancer activity towards TNBC-sensitive and -resistant to cisplatin**

**Martin Vojtek<sup>1,†</sup>, Clara B. Martins<sup>2,†</sup>, Raquel Ramos<sup>1</sup>, Sara Gomes Duarte<sup>1</sup>, Isabel M. P. L. V. O. Ferreira<sup>3</sup>, Ana L. M. Batista de Carvalho<sup>2</sup>, M. Paula M. Marques<sup>2,4</sup> and Carmen Diniz<sup>1</sup>**


<sup>1</sup> LAQV/REQUIMTE, Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal

<sup>2</sup> Molecular Physical-Chemistry R&D Unit, Department of Chemistry, University of Coimbra, 3004-535 Coimbra, Portugal

<sup>3</sup> LAQV/REQUIMTE, Laboratory of Bromatology and Hydrology, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal;

<sup>4</sup> Department of Life Sciences, Faculty of Science and Technology, University of Coimbra, 3000-456 Coimbra, Portugal.

**Supplementary Material**



**Figure S1.** Impact of increasing concentrations of Pd<sub>3</sub>Spd<sub>2</sub> or Pt<sub>3</sub>Spd<sub>2</sub> on TNBC. Dose–response curves of Pd<sub>3</sub>Spd<sub>2</sub> (upper panel) and Pt<sub>3</sub>Spd<sub>2</sub> (lower panel) in breast cancer MDA-MB-231 and MDA-MB-231/R cell at 24, 48 and 72 h of incubation obtained through the SRB assay. Values are expressed as mean ± SEM from 4 independent experiments (in triplicate). Data points with no visible error bars have errors smaller than the size of the symbol.